TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 15601806
Drug: Intravenous administration
Normalized name: intravenous administration set
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous administration of rHA
Study: 15601806
Drug: Intravenous administration
Normalized name: intravenous administration set
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous administration of HSA
Study: 7794983
Drug: Community-based arthritis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Community-based arthritis education program (6 weekly sessions of 2.5 hours' duration)
Study: 9668369
Drug: GM1 ganglioside
Normalized name: Porcine GM1 ganglioside
DrugBank: Ganglioside GM1 (DB16948)
Approvals — FDA: no, EMA: no, PMDA: no
Description: GM1 ganglioside treatment
Study: 376054
Drug: Cimetidine 800
Normalized name: cimetidine 800 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cimetidine 800 mg daily for six weeks
Study: 376054
Drug: Carbenoxolone sodium
Normalized name: carbenoxolone sodium
DrugBank: Carbenoxolone (DB02329)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carbenoxolone sodium 300 mg daily for one week then 150 mg daily for five weeks
Study: 31112957
Drug: Levofloxacin (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levofloxacin (500 mg per day for 4 weeks)
Study: 31112957
Drug: Levofloxacin and
Normalized name: levofloxacin and ornidazole
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levofloxacin and azithromycin combination
Study: 28068121
Drug: Culturally adapted
Normalized name: casein, emmental cultured
Approvals — FDA: no, EMA: no, PMDA: no
Description: Culturally adapted Motivational Enhancement Therapy delivered in Spanish
Study: 25807939
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg daily dose of delayed-release prednisone
Study: 24516413
Drug: Actovegin (2,000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Actovegin (2,000 mg/day for up to 20 intravenous infusions followed by 1,200 mg/day orally)
Study: 18037817
Drug: Duloxetine (40,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Duloxetine (40, 60, 80, 120 mg/day)
Study: 18037817
Drug: SSRIs (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: SSRIs (10 mg/day escitalopram, 20 mg/day fluoxetine and paroxetine)
Study: 15239013
Drug: Titanium implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Titanium implant (Bak‐C; Spine‐Tech, Minneapolis)
Study: 10958599
Drug: Amifostine (910
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amifostine (910 mg/m2) given as a short infusion prior to cisplatin
Study: 15036788
Drug: Omeprazole (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole (80 mg)
Study: 28157653
Drug: Suppository +
Normalized name: Rectal Suppository
Approvals — FDA: no, EMA: no, PMDA: no
Description: Suppository + vaginal cream + oral vitamin B complex (group C)
Study: 28157653
Drug: Suppository +
Normalized name: Rectal Suppository
Approvals — FDA: no, EMA: no, PMDA: no
Description: Suppository + oral antifungal agents (group A)
Study: 28157653
Drug: Suppository +
Normalized name: Rectal Suppository
Approvals — FDA: no, EMA: no, PMDA: no
Description: Suppository + vaginal cream (group B)
Study: 26446482
Drug: High-dose soy
Normalized name: soy acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose soy (HDS) - 2 soy muffins containing 25 g soy protein
Study: 26446482
Drug: Low-dose soy
Normalized name: soy acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-dose soy (LDS) - 1 soy and 1 wheat muffin containing 12.5 g soy protein and 12.5 g whey protein
Study: 26446482
Drug: Control -
Normalized name: HISTAMINE 6 mg in 1 mL PERCUTANEOUS INJECTION [Positive Skin Test Control - Histamine]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control - 2 wheat muffins containing 25 g whey protein
Study: 21670457
Drug: Intramuscular injection
Normalized name: rabies, intramuscular injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular injection of depot hydroxyprogesterone 500 mg 5 to 14 days before surgery
Study: 17098421
Drug: pviFOX (oxaliplatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: pviFOX (oxaliplatin plus protracted infusion of 5‐fluorouracil)
Study: 11294041
Drug: Mianserin (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mianserin (30 mg/day)
Study: 9447285
Drug: Leuprolide acetate
Normalized name: Leuprolide Acetate
DrugBank: Leuprolide (DB00007)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Leuprolide acetate (LH‐RH agonist: LHRH‐A)
Study: 29689636
Drug: HIFU started
Normalized name: venetoclax
DrugBank: Venetoclax (DB11581)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: HIFU started 1 minute after SonoVue injection
Study: 29689636
Drug: HIFU started
Normalized name: venetoclax
DrugBank: Venetoclax (DB11581)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: HIFU started 10 minutes after SonoVue injection
Study: 27704865
Drug: Local thermal
Normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local thermal therapy for 2 weeks
Study: 27704865
Drug: Local thermal
Normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local thermal therapy
Study: 21711204
Drug: 1600 mg
Normalized name: glycerin 1600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1600 mg Avena sativa herb extract
Study: 21711204
Drug: 0 mg
Normalized name: RNA 180 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0 mg Avena sativa herb extract
Study: 21711204
Drug: 2400 mg
Normalized name: pancreatin 2400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2400 mg Avena sativa herb extract
Study: 15558393
Drug: 9-month, twice-weekly
Approvals — FDA: no, EMA: no, PMDA: no
Description: 9-month, twice-weekly exercise program (n = 11)
Study: 9236555
Drug: Intramuscular immune
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular immune serum globulin (4 mL of 16% polyvalent immune serum globulin every 2 months, n = 450)
Study: 8353585
Drug: Arterial line
Normalized name: Echinacea, aerial parts
Approvals — FDA: no, EMA: no, PMDA: no
Description: Arterial line sample with discard volume deadspace + 2 mL
Study: 8353585
Drug: Arterial line
Normalized name: Echinacea, aerial parts
Approvals — FDA: no, EMA: no, PMDA: no
Description: Arterial line sample with discard volume deadspace + 4 mL
Study: 31965072
Drug: Liraglutide (1.8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liraglutide (1.8 mg/d)
Study: 9458325
Drug: PALA (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: PALA (250 mg/m² on day 1) + FA (20 mg/m²) + 5-FU (400 mg/m², 5 min i.v. bolus injection) on days 2-5
Study: 9458325
Drug: 5-FU (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5-FU (400 mg/m², 5 min i.v. bolus injection) + FA (20 mg/m²) on days 2-5 without PALA
Study: 2229705
Drug: Treatment group
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment group (education and psychological support in addition to routine care)
Study: 11774104
Drug: Fluvastatin 40
Normalized name: fluvastatin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluvastatin 40 mg/d for 8 weeks
Study: 30485325
Drug: Dengue immunoglobulin
Normalized name: immunoglobulin A
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dengue immunoglobulin G titres in children with prior medical diagnosis of dengue infection
Study: 30485325
Drug: Dengue immunoglobulin
Normalized name: immunoglobulin A
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dengue immunoglobulin G titres in children without prior medical diagnosis of dengue infection
Study: 30485325
Drug: Dengue immunoglobulin
Normalized name: immunoglobulin A
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dengue immunoglobulin G levels above the median value
Study: 27919284
Drug: ML Flow
Approvals — FDA: no, EMA: no, PMDA: no
Description: ML Flow test positivity
Study: 24747100
Drug: ICD therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: ICD therapy episodes for life-threatening VA
Study: 24747100
Drug: ICD therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: ICD therapy episodes for life-threatening VA in patients not on beta-blocker therapy
Study: 20518617
Drug: Perindopril/indapamide fixed-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perindopril/indapamide fixed-dose combination
Study: 15985013
Drug: Cycled IL-2
Normalized name: Ile
DrugBank: Isoleucine (DB00167)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cycled IL-2 plus antiretroviral therapy (ART)
Study: 10646049
Drug: Racecadotril (1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Racecadotril (1.5 mg/kg three times daily)
Study: 10646049
Drug: Loperamide (0.03
Approvals — FDA: no, EMA: no, PMDA: no
Description: Loperamide (0.03 mg/kg three times daily)
Study: 1804731
Drug: Conventional therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional therapy (including antispasmodic Colpermin)
Study: 6683632
Drug: Adriamycin-cyclophosphamide (6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adriamycin-cyclophosphamide (6 courses) + Levamisole (immunotherapy for 2 years)
Study: 27456494
Drug: Prebiotics (oligofructose-enriched
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prebiotics (oligofructose-enriched inulin 8 g orally/day)
Study: 27456494
Drug: Placebo (maltodextrin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (maltodextrin 3.3 g orally/day)
Study: 20963579
Drug: Transcranial Magnetic
Normalized name: transcranial magnetic stimulator
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transcranial Magnetic Stimulation (TMS) over left ventral premotor cortex (L-PMv)
Study: 20963579
Drug: Transcranial Magnetic
Normalized name: transcranial magnetic stimulator
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transcranial Magnetic Stimulation (TMS) over left dorsal premotor cortex (L-PMd)
Study: 17331650
Drug: Betadine ointment
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Betadine ointment gauzes (Group B)
Study: 17331650
Drug: Betadine ointment
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Betadine ointment gauzes (Group D)
Study: 16279563
Drug: Food elimination
Normalized name: ALLERGENIC EXTRACT, FOOD, WHEAT
DrugBank: Wheat (DB10579)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Food elimination diet based on skin prick and atopy patch testing results
Study: 8497364
Drug: 0.75% metronidazole
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.75% metronidazole vaginal gel
Study: 475943
Drug: Bupropion 50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupropion 50 mg
Study: 475943
Drug: Amitriptyline 25
Normalized name: amitriptyline 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amitriptyline 25 mg (base)
Study: 475943
Drug: Dexamphetamine 5
Normalized name: Dexamphetamine
DrugBank: Dextroamphetamine (DB01576)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamphetamine 5 mg
Study: 31094803
Drug: 8-mg dexamethasone
Normalized name: dexamethasone 8 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8-mg dexamethasone
Study: 22574814
Drug: Placebo cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo cream (n=19)
Study: 19713257
Drug: Gabapentin (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gabapentin (3 x 400 mg)
Study: 19713257
Drug: Phenytoin (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phenytoin (3 x 100 mg)
Study: 12394224
Drug: Ranitidine bismuth
Normalized name: RANITIDINE BISMUTH CITRATE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranitidine bismuth citrate (RBC) 400 mg B.I.D., clarithromycin (C) 500 mg B.I.D., metronidazole (M) 500 mg every morning and 1,000 mg every evening for 14 days
Study: 12394224
Drug: Previous treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Previous treatment with omeprazole (O) 20 mg, clarithromycin (C) 250 mg, metronidazole (M) 500 mg
Study: 12394224
Drug: Previous treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Previous treatment with ranitidine bismuth citrate (RBC) 400 mg, tetracycline (T) 1,000 mg, metronidazole (M) 500 mg
Study: 9917784
Drug: Subconjunctival mitomycin
Normalized name: Mitomycin
DrugBank: Mitomycin (DB00305)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subconjunctival mitomycin C (0.25 ml of 0.2 mg/ml)
Study: 8772214
Drug: Adjusted-dose oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjusted-dose oral anticoagulants (OAC) - acenocoumarol, target INR 2.0-3.0
Study: 8772214
Drug: Fixed-dose subcutaneous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed-dose subcutaneous low molecular weight heparin (LMWH) - nadroparine, 60 aXa IU/kg once daily
Study: 8772214
Drug: Adjusted-dose oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjusted-dose oral anticoagulants (OAC)
Study: 8772214
Drug: Fixed-dose subcutaneous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed-dose subcutaneous low molecular weight heparin (LMWH) - nadroparine
Study: 28880416
Drug: Standard osteoarthritis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard osteoarthritis treatment (Control)
Study: 27690505
Drug: Daily (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily (25 mg) plus targeted (25 mg) naltrexone
Study: 17522511
Drug: Multimodal management
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multimodal management protocol (intravenous fluid restriction, unrestricted oral intake with prokinetic agents, early ambulation, fixed regimen epidural analgesia)
Study: 17522511
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (intravenous fluids to prevent oliguria, restricted oral intake until return of bowel motility, weaning regimen epidural analgesia)
Study: 15199352
Drug: Pharmacologic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmacologic treatment for hyperlipidemia
Study: 15199352
Drug: Treatment for
Normalized name: Hair Regrowth Treatment For Men
DrugBank: Minoxidil (DB00350)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Treatment for hyperlipidemia
Study: 3579683
Drug: Conventional speech
Normalized name: TRACH TUBE,SPEECH SZ 10 BLOM #313-30-100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional speech therapy provided by professional speech pathologists twice weekly
Study: 3579683
Drug: Emotionally supportive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Emotionally supportive counseling therapy provided by professional speech pathologists at the same intervals
Study: 786317
Drug: sympathomimetic drug
Normalized name: Sympathomimetics
Approvals — FDA: no, EMA: no, PMDA: no
Description: sympathomimetic drug
Study: 28668914
Drug: Dexmedetomidine (0.1-0.7
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine (0.1-0.7 μg/kg per hour, titrated by patient-triggered doses of 0.25 μg/kg)
Study: 27684818
Drug: Low-dose CT
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose CT with iterative model reconstruction (IMR)
Study: 27684818
Drug: Low-dose CT
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose CT with hybrid iterative reconstruction (HIR)
Study: 27684818
Drug: Low-dose CT
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose CT with filtered back projection (FBP)
Study: 27684818
Drug: Routine-dose CT
Normalized name: brompheniramine tannate Chewable Tablet [BroveX CT]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine-dose CT with filtered back projection (FBP)
Study: 24439687
Drug: Psychosomatic day
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psychosomatic day hospital treatment
Study: 19197129
Drug: Remifentanil and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remifentanil and propofol administered by TCI (blood concentration: 3-5 microg/L for remifentanil and 3-5 mg/L for propofol)
Study: 19197129
Drug: Fentanyl and
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Fentanyl and propofol administered by TCI (fentanyl infusion: 2-3 microg/(kg.h), same propofol concentration as Group R)
Study: 17496586
Drug: Topical application
Normalized name: Talc Topical application Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical application of completely autologous platelet gel
Study: 11913682
Drug: Postoperative application
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Postoperative application of estriol ointment (n = 14)
Study: 11913682
Drug: Postoperative application
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Postoperative application of dexpanthenol ointment (n = 12)
Study: 7796767
Drug: Purified Vi
Normalized name: VIS-410
DrugBank: VIS-410 (DB19067)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Purified Vi polysaccharide vaccine (Typhim Vi), single intramuscular injection.
Study: 3038428
Drug: Captopril 25
Normalized name: captopril 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Captopril 25 mg tid
Study: 2893080
Drug: Frusemide 40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Frusemide 40 mg daily
Study: 21249382
Drug: Highly fit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Highly fit adolescent football players (peak VO(2) 43.5 ± 3.4 ml kg(‐1) min(‐1))
Study: 21249382
Drug: Untrained girls
Normalized name: minoxidil
DrugBank: Minoxidil (DB00350)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Untrained girls (peak VO(2) 36.0 ± 5.1 ml kg(‐1) min(‐1))
Study: 19963157
Drug: 20 mL
Normalized name: Exact-Med, 20 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mL apple cider vinegar, 40 mL water
Study: 19963157
Drug: 60 mL
Normalized name: Disposable Nurser 60 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 mL water (placebo)
Study: 14551525
Drug: Early statin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Early statin therapy
Study: 12215193
Drug: Control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (no early statin therapy)
Study: 8570063
Drug: Cefotiam (single
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefotiam (single dose)
Study: 2773842
Drug: Intramuscular or
Normalized name: Medicated Pad or Tape
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular or oral administration of iron
Study: 790551
Drug: Ketoprofen 100
Normalized name: ketoprofen 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketoprofen 100 mg daily
Study: 790551
Drug: Acetylsalicylic acid
Normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Acetylsalicylic acid 3 g daily
Study: 30520201
Drug: 1 hour
Normalized name: Product containing precisely estradiol 312.5 nanogram/1 hour prolonged-release vaginal ring (clinical drug)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 hour ≥ 155 mg/dL
Study: 22929469
Drug: Medical management
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medical management consisting of intravenous fluids, prophylactic antibiotics, blood transfusions, anti-diarrheals, analgesics, and nutrition
Study: 20334973
Drug: High-Risk Experimental
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-Risk Experimental (monthly urine screens, compliance checklists, individual and group motivational counseling)
Study: 16320858
Drug: 0.625 mg
Normalized name: estrone 0.625 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.625 mg conjugated equine estrogen (CEE) daily and twice daily 20 mg transdermal progesterone cream (PC)
Study: 16320858
Drug: 0.625 mg
Normalized name: estrone 0.625 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.625 mg conjugated equine estrogen (CEE) daily and 2.5 mg medroxyprogesterone acetate (MPA)
Study: 12193430
Drug: Growth hormone
Normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Growth hormone (GH) treatment at 6.0 IU/m2/day for at least two years
Study: 2698571
Drug: Gallopamil retard
Normalized name: gallopamil
DrugBank: Gallopamil (DB12923)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gallopamil retard at a dosage of 75 mg b.i.d.
Study: 62991
Drug: No tablets
Normalized name: caffeine Oral Tablet [No Doz]
DrugBank: Nitric Oxide (DB00435)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: No tablets at all
Study: 21559803
Drug: Alcohol (n=37;
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alcohol (n=37; average peak BAC=0.087 g/100 ml)
Study: 16374471
Drug: Topical methyl
Normalized name: methylal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical methyl 5-aminolevulinate (MAL) cream at concentrations of 16-160 mg/g applied for 3 hours and 18 hours.
Study: 16374471
Drug: Topical methyl
Normalized name: methylal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical methyl 5-aminolevulinate (MAL) cream at concentrations of 16-160 mg/g applied for 18 hours.
Study: 8721273
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg itraconazole a day orally for 4 days
Study: 8134169
Drug: Formula containing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Formula containing 0.13 mumol/L (10 micrograms/L) Se
Study: 8134169
Drug: Formula containing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Formula containing 0.26‐0.33 mumol/L (20‐25 micrograms/L) Se (suggested)
Study: 2891518
Drug: LH-RH nasal
Normalized name: LH
DrugBank: Luteinizing hormone (DB14741)
Approvals — FDA: no, EMA: no, PMDA: no
Description: LH-RH nasal spray
Study: 2891518
Drug: LH-RH nasal
Normalized name: LH
DrugBank: Luteinizing hormone (DB14741)
Approvals — FDA: no, EMA: no, PMDA: no
Description: LH-RH nasal spray (including subsequent open study and second course)
Study: 7259838
Drug: All treatment
Normalized name: UNDECYLENIC ACID 8 g in 30 mL / TOLNAFTATE 1 g in 30 mL TOPICAL LIQUID [Fugal nall treatment]
Approvals — FDA: no, EMA: no, PMDA: no
Description: All treatment options
Study: 12190760
Drug: Single intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single intravenous cannula used for both intra‐operative and postoperative purposes
Study: 7850328
Drug: Neoadjuvant or
Normalized name: Medicated Pad or Tape
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant or concurrent single-agent cisplatin followed by local definitive treatment
Study: 7850328
Drug: Chemotherapy (cisplatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy (cisplatin and doxorubicin)
Study: 2182103
Drug: Spectacles treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spectacles treatment
Study: 2182103
Drug: Spectacles treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spectacles treatment (subgroup of consistent wearers)
Study: 2182103
Drug: Spectacles treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spectacles treatment (subgroup of inconsistent wearers)
Study: 21310088
Drug: PURIAM110 dietary
Normalized name: sodium phosphate, monobasic
DrugBank: Sodium phosphate, monobasic (DB09449)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: PURIAM110 dietary supplement
Study: 11506108
Drug: Hydration with
Normalized name: Gold Bond Healing Hydration with Aloe Cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydration with 15 ml/kg crystalloid immediately before spinal anesthesia